NDA 204655 · Astrazeneca Lp
Nexium 24hr
Esomeprazole Magnesium · Oral
Last checked: Nov 20, 2026Latest source record: Sep 6, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2014
Mar 28, 2014
Approved uses
1
Original approval plus efficacy supplements
Registered trials
522
102 Phase 3, 23 recruiting
FAERS reports
42,419
34,323 serious, 3,791 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect May 14, 2024.
Uses treats frequent heartburn (occurs 2 or more days a week) not intended for immediate relief of heartburn; this drug may take 1 to 4 days for full effect
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- NEXIUM 24HR · ESOMEPRAZOLE MAGNESIUM EQ 20MG BASE · CAPSULE, DELAYED RELEASE, ORAL · Over-the-counter
Clinical trials
Interventional ClinicalTrials.gov studies with "Esomeprazole" as an intervention, any sponsor and status, largest first.
- Multicentric Randomized Study of H. Pylori Eradication and Pepsinogen Testing for Prevention of Gastric Cancer MortalityPivotal-lookingRecruiting
International Agency for Research on CancerAcademic, hospital or other
NCT02047994 · 30,000 participants (planned) · Start Mar 2013 · Primary completion Dec 2033
Drug: Triple therapy · For: Helicobacter Pylori Infections; Atrophic Gastritis; Gastric Cancer
Sites: Riga, Latvia
- Community-based Helicobacter Pylori EradicationStatus unknown
National Taiwan University HospitalAcademic, hospital or other
NCT00155389 · 5,000 participants (planned) · Start Jan 2004 · Primary completion Dec 2015
Drug: Helicobacter pylori eradication · For: Helicobacter Pylori Infection
Sites: Taipei, Taiwan · 2 sites in all
- Eradication of Helicobacter Pylori Subtypes at High Gastric Cancer Risk: a Cluster-randomized Controlled TrialPivotal-lookingNot yet recruiting
Fudan UniversityAcademic, hospital or other
NCT06943794 · 4,824 participants (planned) · Start Mar 30, 2026 · Primary completion May 1, 2030
Drug: recommendations for Hp eradication treatment · For: Gastric (Stomach) Cancer
Sites: Tongling, China
- Nexium (Esomeprazole) in Symptom Adapted Therapy in GERD PatientsPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT00444275 · 3,029 participants · Start Mar 2007 · Primary completion Oct 2008
Drug: esomeprazole (Nexium®); Xolaam® · For: GERD
Sites: Rouen, France
- A Multi-center Study for Individual Treatment of Helicobacter Pylori InfectionPivotal-lookingStatus unknown
First Affiliated Hospital of Zhejiang UniversityAcademic, hospital or other
NCT02689583 · 3,000 participants (planned) · Start Mar 2016 · Primary completion Mar 2017
Drug: Antibiotic selection based on the antibiotic susceptibility testing · For: Gastritis; Gastric Ulcer
- A Phase III, Randomized, Study of Aspirin and Esomeprazole Chemoprevention in Barrett's MetaplasiaPivotal-lookingCompleted
University of OxfordAcademic, hospital or other
NCT00357682 · 2,557 participants · Start Mar 10, 2005 · Primary completion May 31, 2017
Drug: Esomeprazole; Esomeprazole and 1 more · For: Esophageal Cancer; Precancerous Condition
- Study of Esomeprazole 20 mg or 40 mg vs Placebo Effectiveness on the Occurrence of Peptic Ulcers in Subjects on Low Dose Acetylsalicylic Acid (LDA)Pivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT00441727 · 2,426 participants · Start Feb 2007 · Primary completion Aug 2008
Drug: Esomeprazole 40 mg; Esomeprazole 20 mg and 1 more · For: Gastric Ulcer; Duodenal Ulcer
Sites: Birmingham, Alabama; Tucson, Arizona; Anaheim, California · 189 sites in all
- Examine National Characteristics & Outcome Measures of GERD Patients Using the PPI Acid Suppression Symptom (PASS) Test for ResponsePivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT00392002 · 2,000 participants · Start Oct 2005
Drug: Esomeprazole · For: Gastroesophageal Reflux
Sites: Mississauga, Canada; Toronto, Canada
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- chronic kidney disease19,478
- acute kidney injury9,970
- renal failure7,889
- renal injury6,117
- end stage renal disease6,040
- drug ineffective2,791
- tubulointerstitial nephritis2,445
- gastrooesophageal reflux disease2,283
- nausea1,827
- pain1,751
- death1,717
- off label use1,550
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 46 |
| 2005 | 72 |
| 2006 | 203 |
| 2007 | 442 |
| 2008 | 772 |
| 2009 | 488 |
| 2010 | 391 |
| 2011 | 385 |
| 2012 | 303 |
| 2013 | 129 |
| 2014 | 741 |
| 2015 | 1,282 |
| 2016 | 1,506 |
| 2017 | 1,362 |
| 2018 | 11,330 |
| 2019 | 10,667 |
| 2020 | 2,444 |
| 2021 | 2,692 |
| 2022 | 1,687 |
| 2023 | 1,408 |
| 2024 | 1,453 |
| 2025 | 1,578 |
| 2026 | 1,038 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparison of vonoprazan bismuth-containing triple therapy with quadruple therapy in Helicobacter pylori-infected treatment-naive patients: a prospective multicenter randomized controlled trial.
Liang JW, Xiong S, Jia YG, et al. · J Gastroenterol Hepatol 2024 · Randomized Controlled Trial, Multicenter Study
- Comparative effectiveness and tolerability of esomeprazole and omeprazole in gastro-esophageal reflux disease: A systematic review and meta-analysis.
Qi Q, Wang R, Liu L, et al. · Int J Clin Pharmacol Ther 2015 · Comparative Study, Meta-Analysis
- Night-time gastric acid suppression by tegoprazan compared to vonoprazan or esomeprazole.
Yang E, Kim S, Kim B, et al. · Br J Clin Pharmacol 2022 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Proton pump inhibitors are not associated with an increased risk of Clostridioides difficile infection: a systematic review and meta-analysis of randomized controlled trials.
Floria DE, Obeidat M, Váncsa S, et al. · Gut Microbes 2025 · Systematic Review, Meta-Analysis
- Bismuth, esomeprazole, metronidazole and amoxicillin or tetracycline as a first-line regimen for Helicobacter pylori eradication: A randomized controlled trial.
Tian XL, Suo BJ, Zhang H, et al. · Helicobacter 2023 · Randomized Controlled Trial
- Randomised phase 3 trial: tegoprazan, a novel potassium-competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis.
Lee KJ, Son BK, Kim GH, et al. · Aliment Pharmacol Ther 2019 · Clinical Trial, Phase III, Comparative Study
Sponsor: AstraZeneca
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.